Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Review: Oncolytic virotherapy, updates and future directions.

Fountzilas C, Patel S, Mahalingam D.

Oncotarget. 2017 May 31;8(60):102617-102639. doi: 10.18632/oncotarget.18309. eCollection 2017 Nov 24. Review.


Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer.

Howells A, Marelli G, Lemoine NR, Wang Y.

Front Oncol. 2017 Sep 8;7:195. doi: 10.3389/fonc.2017.00195. eCollection 2017. Review.


Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.

Chen A, Zhang Y, Meng G, Jiang D, Zhang H, Zheng M, Xia M, Jiang A, Wu J, Beltinger C, Wei J.

Sci Rep. 2017 Jul 12;7(1):5170. doi: 10.1038/s41598-017-05500-z.


Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.

Jing Y, Chavez V, Ban Y, Acquavella N, El-Ashry D, Pronin A, Chen X, Merchan JR.

Mol Cancer Res. 2017 Oct;15(10):1410-1420. doi: 10.1158/1541-7786.MCR-17-0016. Epub 2017 Jul 5.


Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.

Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL.

Front Immunol. 2017 May 15;8:555. doi: 10.3389/fimmu.2017.00555. eCollection 2017. Review.


Delivering safer immunotherapies for cancer.

Milling L, Zhang Y, Irvine DJ.

Adv Drug Deliv Rev. 2017 May 15;114:79-101. doi: 10.1016/j.addr.2017.05.011. Epub 2017 May 22. Review.


Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.

Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E.

Curr Cancer Drug Targets. 2018;18(2):177-187. doi: 10.2174/1568009617666170222125035.


Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.

Babiker HM, Riaz IB, Husnain M, Borad MJ.

Oncolytic Virother. 2017 Feb 9;6:11-18. doi: 10.2147/OV.S100072. eCollection 2017. Review.


Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells.

Achard C, Guillerme JB, Bruni D, Boisgerault N, Combredet C, Tangy F, Jouvenet N, Grégoire M, Fonteneau JF.

Oncoimmunology. 2016 Nov 18;6(1):e1261240. doi: 10.1080/2162402X.2016.1261240. eCollection 2017.


Potential and clinical translation of oncolytic measles viruses.

Robinson S, Galanis E.

Expert Opin Biol Ther. 2017 Mar;17(3):353-363. doi: 10.1080/14712598.2017.1288713. Review.


Ultrasensitive Luminescent In Vitro Detection for Tumor Markers Based on Inorganic Lanthanide Nano-Bioprobes.

Zheng W, Zhou S, Xu J, Liu Y, Huang P, Liu Y, Chen X.

Adv Sci (Weinh). 2016 Oct 20;3(11):1600197. eCollection 2016 Nov.


A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity.

Nosaki K, Hamada K, Takashima Y, Sagara M, Matsumura Y, Miyamoto S, Hijikata Y, Okazaki T, Nakanishi Y, Tani K.

Mol Ther Oncolytics. 2016 Nov 2;3:16022. eCollection 2016.


Measles to the Rescue: A Review of Oncolytic Measles Virus.

Aref S, Bailey K, Fielding A.

Viruses. 2016 Oct 22;8(10). pii: E294. Review.


Targeting tumor vasculature through oncolytic virotherapy: recent advances.

Toro Bejarano M, Merchan JR.

Oncolytic Virother. 2015 Nov 11;4:169-81. doi: 10.2147/OV.S66045. eCollection 2015. Review.


Oncolytic virotherapy for human malignant mesothelioma: recent advances.

Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau JF.

Oncolytic Virother. 2015 Sep 10;4:133-40. doi: 10.2147/OV.S66091. eCollection 2015. Review.


Advances in the design and development of oncolytic measles viruses.

Hutzen B, Raffel C, Studebaker AW.

Oncolytic Virother. 2015 Aug 27;4:109-18. doi: 10.2147/OV.S66078. eCollection 2015. Review.


Cell carriers for oncolytic viruses: current challenges and future directions.

Roy DG, Bell JC.

Oncolytic Virother. 2013 Oct 9;2:47-56. doi: 10.2147/OV.S36623. eCollection 2013. Review.


Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition.

Fernandes J.

Biomark Cancer. 2016 Jul 28;8:101-10. doi: 10.4137/BIC.S33378. eCollection 2016. Review.


Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.

Ruf B, Berchtold S, Venturelli S, Burkard M, Smirnow I, Prenzel T, Henning SW, Lauer UM.

Mol Ther Oncolytics. 2015 Oct 7;2:15019. doi: 10.1038/mto.2015.19. eCollection 2015.

Supplemental Content

Support Center